Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromodomain Y-linked protein 2A (CDY2A) is a Y-chromosome–encoded, intronless protein characterized by an N-terminal chromodomain and a C-terminal histone acetyltransferase domain. CDY2A is mainly expressed in testis, localized to the nucleus of late spermatids, and is implicated in facilitating histone hyperacetylation. This epigenetic modification is crucial for replacing histones with protamines—an essential step for sperm DNA compaction and maturation. Chromodomain proteins, including CDY2A, are components of heterochromatin-like complexes and can act as gene repressors. Mutations or deletions in CDY2A are implicated in certain types of spermatogenic failure (a cause of male infertility). There are no drugs known to interact with this molecule, and it does not serve as a current therapeutic target in clinical applications. There are paralogs such as CDY2B, and the chromodomain Y family is generally involved in chromatin regulation, but CDY2A itself has a highly specialized, testis-specific function.
No drugs target CDY2A directly; known mechanisms are epigenetic/chromatin regulation by the endogenous protein
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromodomain Y-linked protein 2A (CDY2A).